The use of lentiviral vectors in gene therapy of leukemia: Combinatorial gene delivery of immunomodulators into leukemia cells by state-of-the-art vectors

Blood Cells, Molecules, and Diseases

Volumn 31, Issue 1, 2003, Pages 28-37

  Stripecke, Renata ^a,b   Koya, Richard C ^a   Ta, Huy Q ^a   Kasahara, Nori ^a,b   Levine, Alexandra M ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD40 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 4; LENTIVIRUS VECTOR; VIRUS PROTEIN;

ARTICLE; CONTROLLED STUDY; EMBRYO; GENE DELIVERY SYSTEM; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSTIMULATION; LEUKEMIA; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VIRAL GENE THERAPY;

INSERTION SEQUENCES; MURINAE;

EID: 0038729332     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1079-9796(03)00062-7     Document Type: Article

References (20)

1. Mayer R.J., Davis R.B., Schiffer C.A., Berg D.T., Powell B.L., Schulman P., Omura G.A., Moore J.O., McIntyre O.R., Frei E. 3rd. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N. Engl. J. Med. 331:1994;896-903.
2. Laport G.F., Larson R.A. Treatment of adult acute lymphoblastic leukemia. Semin. Oncol. 24:1997;70-82.
3. Gaiger A., Reese V., Disis M.L., Cheever M.A. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood. 96:2000;1480-1489.
4. Scheibenbogen C., Letsch A., Thiel E., Schmittel A., Mailaender V., Baerwolf S., Nagorsen D., Keilholz U. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood. 100:2002;2132-2137.
5. Molldrem J., Dermime S., Parker K., Jiang Y.Z., Mavroudis D., Hensel N., Fukushima P., Barrett A.J. Targeted T-cell therapy for human leukemia cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells . Blood. 88:1996;2450-2457.
6. Collins R.H. Jr., Shpilberg O., Drobyski W.R., Porter D.L., Giralt S., Champlin R., Goodman S.A., Wolff S.N., Hu W., Verfaillie C., List A., Dalton W., Ognoskie N., Chetrit A., Antin J.H., Nemunaitis J. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 15:1997;433-444.
7. Stripecke R., Levine A.M., Pullarkat V., Cardoso A.A. Immunotherapy with acute leukemia cells modified into antigen-presenting cells ex vivo culture and gene transfer methods . Leukemia. 16:2002;1974-1983.
8. Stripecke R., Cardoso A.A., Pepper K.A., Skelton D.C., Yu X.J., Mascarenhas L., Weinberg K.I., Nadler L.M., Kohn D.B. Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage-colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses. Blood. 96:2000;1317-1326.
9. Koya R.C., Kasahara N., Pullarkat V., Levine A.M., Stripecke R. Transduction of acute myeloid leukemia cells with third generation self-inactivating lentiviral vectors expressing CD60 and GMCSF: effects on proliferation, differentiation, and stimulation of allogeneic and autologous anti-leukemia immune responses effects on proliferation . Leukemia. 16:2002;1645-1654.
10. Stripecke R., Skelton D.C., Pattengale P.K., Shimada H., Kohn D.B. Combination of CD80 and granulocyte-macrophage colony-stimulating factor coexpression by a leukemia cell vaccine preclinical studies in a murine model recapitulating Philadelphia chromosome-positive acute lymphoblastic leukemia . Hum. Gene Ther. 10:1999;2109-2122.
11. Dunussi-Joannopoulos K., Weinstein H.J., Arceci R.J., Croop J.M. Gene therapy with B7.1 and GM-CSF vaccines in a murine AML model. J. Pediatr. Hematol. Oncol. 19:1997;536-540.
12. Vereecque R., Buffenoir G., Preudhomme C., Hetuin D., Bauters F., Fenaux P., Quesnel B. Gene transfer of GM-CSF, CD80 and CD154 cDNA enhances survival in a murine model of acute leukemia with persistence of a minimal residual disease. Gene Ther. 7:2000;1312-1316.
13. Mascarenhas L., Stripecke R., Case S.S., Xu D., Weinberg K.I., Kohn D.B. Gene delivery to human B-precursor acute lymphoblastic leukemia cells. Blood. 92:1998;3537-3545.
14. Biagi E., Bambacioni F., Gaipa G., Casati C., Golay J., Biondi A., Introna M. Efficient lentiviral transduction of primary human acute myelogenous and lymphoblastic leukemia cells. Haematologica. 86:2001;13-16.
15. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 272:1996;263-267.
16. Zufferey R., Nagy D., Mandel R.J., Naldini L., Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15:1997;871-875.
17. Dull T., Zufferey R., Kelly M., Nguyen M., Trono D., Naldini L. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72:1998;8463-8471.
18. Zufferey R., Dull T., Mandel R.J., Bukovsky A., Quiroz D., Naldini L., Trono D. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72:1998;9873-9880.
19. R. Zufferey, J.E. Donello, D. Trono, T.J. Hope, Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J. Virol. 73, 2886-2892.
20. Follenzi A., Ailles L.E., Bakovic S., Geuna M., Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat. Genet. 25:2000;217-222.